Background The Randomized Aldactone Evaluation Study (RALES) demonstrated that
spironolactone significantly improves outcomes in patients with severe heart failure. Use of …

Objectives: This study was designed to determine the adequacy of monitoring patients
receiving spironolactone as well as spironolactone's relationship to hyperkalemia …

Background. Recent studies have shown a fall in global mortality with minimal side effects in
severe congestive heart failure (CHF) patients receiving angiotensin-converting enzyme …

Background—Concerns have been raised about the appropriateness of spironolactone use
in some patients with heart failure. We studied the adoption of spironolactone therapy after …

Objectives: This study investigated the influence of baseline and worsening renal function
(WRF) on the efficacy of spironolactone in patients with severe heart failure (HF) …

The present study enrolled 214 patients, aged 26 to 83 years, with symptomatic New York
Heart Association class II through IV congestive heart failure. Patients were continued on …

Objectives: This study was designed to investigate the appropriateness and complications of
the use of spironolactone for heart failure (HF) in clinical practice. Background …

Purpose: The beneficial effects of spironolactone are additive to those of ACE inhibitors
among patients with heart failure and/or hypertension; however, it is essential to identify …

BACKGROUND: Treatment with spironolactone (SPL) is beneficial in patients with severe
congestive heart failure (CHF). In the Randomized Aldactone Evaluation Study SPL was …

Background—Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone
Antagonist (TOPCAT) patients with heart failure and preserved left ventricular ejection …